GT200600307A - Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina - Google Patents

Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Info

Publication number
GT200600307A
GT200600307A GT200600307A GT200600307A GT200600307A GT 200600307 A GT200600307 A GT 200600307A GT 200600307 A GT200600307 A GT 200600307A GT 200600307 A GT200600307 A GT 200600307A GT 200600307 A GT200600307 A GT 200600307A
Authority
GT
Guatemala
Prior art keywords
oral
demetilvenlafaxin
succinate
hours
disposal
Prior art date
Application number
GT200600307A
Other languages
English (en)
Inventor
Syed N Shah
Mahdi B Fawzi
Christopher Richard Diorio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600307A publication Critical patent/GT200600307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ES DESCRITA UNA FORMA DE DOSIFICACIÓN UNITARIA ORAL, ALTAMENTE BIODISPONIBLE DE SUCCINATO DE O-DESMETILVENLAFAXINA (DVS) QUE POSEE UNA LIBERACIÓN RETARDADA DE AL MENOS UNA HORA Y UNA LIBERACIÓN SOSTENIDA DURANTE VARIAS HORAS PARA PROVEER UNA LIBERACIÓN TOTAL SUPERIOR A 85% DENTRO DE 12 A 14 HORAS APROXIMADAMENTE. EN UNA REALIZACIÓN, LA COMPOSICIÓN DE DVS SUPERBIODISPONIBLE POSEE UNA LIBERACIÓN RETARDADA DE APROXIMADAMENTE DOS HORAS Y UNA LIBERACIÓN TOTAL APROXIMADAMENTE SUPERIOR A 95% DENTRO DE 12 A 14 HORAS. TAMBIÉN ES DESCRITO EL USO DE LA FORMULACIÓN EN EL TRATAMIENTO DE LA DEPRESIÓN Y EN LA REDUCCIÓN DE EFECTOS COLATERALES GASTROINTESTINALES DE O-DESMETILVENLAFAXINA (ODV).
GT200600307A 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina GT200600307A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
GT200600307A true GT200600307A (es) 2008-04-24

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600307A GT200600307A (es) 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Country Status (20)

Country Link
US (1) US20070014859A1 (es)
EP (1) EP1904040A2 (es)
JP (1) JP2009501233A (es)
KR (1) KR20080025405A (es)
CN (1) CN101247791A (es)
AR (1) AR054833A1 (es)
AU (1) AU2006270315A1 (es)
BR (1) BRPI0613484A2 (es)
CA (1) CA2612960A1 (es)
CR (1) CR9626A (es)
EC (1) ECSP088106A (es)
GT (1) GT200600307A (es)
IL (1) IL188313A0 (es)
MX (1) MX2008000666A (es)
NO (1) NO20080088L (es)
PE (1) PE20070192A1 (es)
RU (1) RU2007148195A (es)
SV (1) SV2008002612A (es)
TW (1) TW200740427A (es)
WO (1) WO2007011619A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
MX2007012167A (es) * 2005-03-31 2007-11-22 Wyeth Corp Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno, y usos del mismo.
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
TW200803892A (en) 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
AU2006322057A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
WO2009049354A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
TR201004720T1 (tr) * 2007-12-10 2010-11-22 Wyeth Llc Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) * 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
KR20160106211A (ko) 2009-04-06 2016-09-09 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
CN102724962B (zh) * 2009-11-09 2017-05-17 惠氏有限责任公司 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
EP2552419A2 (en) * 2010-03-31 2013-02-06 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
CA2554559A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
US20070014859A1 (en) 2007-01-18
SV2008002612A (es) 2008-08-29
JP2009501233A (ja) 2009-01-15
IL188313A0 (en) 2008-04-13
NO20080088L (no) 2008-04-02
ECSP088106A (es) 2008-02-20
RU2007148195A (ru) 2009-08-20
KR20080025405A (ko) 2008-03-20
CA2612960A1 (en) 2007-01-25
CN101247791A (zh) 2008-08-20
WO2007011619A2 (en) 2007-01-25
AU2006270315A1 (en) 2007-01-25
CR9626A (es) 2008-04-10
EP1904040A2 (en) 2008-04-02
PE20070192A1 (es) 2007-03-16
BRPI0613484A2 (pt) 2016-11-16
WO2007011619A3 (en) 2007-06-21
MX2008000666A (es) 2008-03-13
TW200740427A (en) 2007-11-01
AR054833A1 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
ES2422556T3 (es) Tratamiento de hepatitis vírica
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
PA8625001A1 (es) Composiciones de pelicula
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
DOP2006000241A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
BRPI0508359A (pt) composições de pelìcula
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
PE20081072A1 (es) Composiciones de anti-histaminicos, descongestivos, antitusivos y drogas anti-inflamatorios no esteroidales
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
PA8586301A1 (es) Formulaciones de liberacion prolongada en forma de suspension
PA8571901A1 (es) Nueva composicion farmaceutica
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
GT200500315A (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
AR045392A1 (es) Composiciones para el tratamiento del cabello